Cat. No. 2580
Alternative Name: CP 66248
Chemical Name: (Z)-5-Chloro-2,3-dihydro-3-(hydroxy
Biological ActivityNSAID that preferentially inhibits COX-1 (IC50 values are < 0.03, 1.2 and > 30 μM for COX-1, COX-2 and 5-lipoxygenase respectively). Inhibits formation of pro-inflammatory arachidonic acid metabolites in isolated human peripheral polymorphonuclear leukocytes. Opener of inward rectifying hKir2.3 channel (EC50 = 402 nM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Liu et al (2002) Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K+ channel hKir2.3. Eur.J.Pharmacol. 435 153. PMID: 11821021.
Kirchner et al (1997) Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J.Pharmacol.Exp.Ther. 282 1094. PMID: 9262379.
Moilanen et al (1988) CP-66,248, a new anti-inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leucocytes in vitro. Eicosanoids 1 35. PMID: 2856170.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Tenidap from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Tenidap, supplier, NSAID, cyclooxygenase, COX-1, inhibitors, inhibits, KIR23, openers, Cyclooxygenase, Oxygenases, Oxidases, Potassium, KIR, Channels, KATP, Inward, Rectifier, K+, CP66248, Tocris Bioscience, Cyclooxygenase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective myeloperoxidase (MPO) inhibitorINCB 024360-analog
Potent indoleamine 2,3-dioxygenase (IDO) inhibitorLM 10
Selective tryptophan 2,3-dioxygenase (TDO) inhibitorNoxA1ds
Potent and selective NADPH oxidase 1 (NOX1) inhibitor
October 30 - November 3, 2016
Boston, MA, USA